Insider Selling: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CEO Sells $4,089,960.00 in Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CEO Yvonne Greenstreet sold 15,148 shares of the firm’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $270.00, for a total value of $4,089,960.00. Following the completion of the sale, the chief executive officer now directly owns 73,441 shares of the company’s stock, valued at $19,829,070. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Yvonne Greenstreet also recently made the following trade(s):

• On Thursday, July 11th, Yvonne Greenstreet sold 7,093 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $261.00, for a total value of $1,851,273.00.
• On Tuesday, June 25th, Yvonne Greenstreet sold 8,301 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $230.99, for a total value of $1,917,447.99.

Alnylam Pharmaceuticals Stock Up 1.3 %

ALNY opened at $272.05 on Monday. The firm has a market cap of $34.41 billion, a price-to-earnings ratio of -101.51 and a beta of 0.37. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $274.93. The business’s 50 day moving average is $208.99 and its two-hundred day moving average is $174.46.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.61. The company had revenue of $659.83 million during the quarter, compared to analyst estimates of $447.22 million. The company’s revenue for the quarter was up 107.0% on a year-over-year basis. During the same period in the previous year, the firm posted ($2.21) EPS. Equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -3.99 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ALNY has been the subject of a number of recent analyst reports. Bank of America raised their price objective on Alnylam Pharmaceuticals from $248.00 to $295.00 and gave the stock a “buy” rating in a research report on Tuesday, June 25th. BMO Capital Markets reissued an “outperform” rating and set a $234.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday, June 24th. Stifel Nicolaus raised their price objective on Alnylam Pharmaceuticals from $215.00 to $295.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. HC Wainwright restated a “buy” rating and set a $400.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday, June 24th. Finally, Evercore ISI raised their target price on Alnylam Pharmaceuticals from $210.00 to $260.00 and gave the company an “outperform” rating in a report on Tuesday, June 25th. Eight analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $269.32.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. ANTIPODES PARTNERS Ltd grew its holdings in Alnylam Pharmaceuticals by 69.1% during the fourth quarter. ANTIPODES PARTNERS Ltd now owns 189,141 shares of the biopharmaceutical company’s stock worth $36,203,000 after acquiring an additional 77,307 shares during the period. Vanguard Group Inc. boosted its position in Alnylam Pharmaceuticals by 2.5% during the fourth quarter. Vanguard Group Inc. now owns 11,943,895 shares of the biopharmaceutical company’s stock worth $2,286,181,000 after purchasing an additional 287,064 shares in the last quarter. Robeco Institutional Asset Management B.V. boosted its position in Alnylam Pharmaceuticals by 155.7% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 12,513 shares in the last quarter. Quattro Financial Advisors LLC boosted its position in Alnylam Pharmaceuticals by 2,517.8% during the first quarter. Quattro Financial Advisors LLC now owns 5,000 shares of the biopharmaceutical company’s stock worth $747,000 after purchasing an additional 4,809 shares in the last quarter. Finally, Westpac Banking Corp boosted its position in Alnylam Pharmaceuticals by 59.8% during the fourth quarter. Westpac Banking Corp now owns 1,512 shares of the biopharmaceutical company’s stock worth $289,000 after purchasing an additional 566 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.